Invex Therapeutics Share Price and Company Fundamentals
Last traded: Today at 4:02 AM
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company has a collaboration with Tessara Therapeutics. Invex Therapeutics Ltd was incorporated in 2019 and is based in Subiaco, Australia.
Key Metrics
PE ratio
-
PB ratio
1.79
Dividend yield
-
Beta
0.23
Market cap
$9.39M
Enterprise value
$4.02M
Company profile
| Industry / Sector | Biotechnology / Healthcare |
|---|---|
| Website | https://www.invextherapeutics.com |
| Mailing address | 38 Rowland Street Level 2 Subiaco WA 6008 Australia |
| Phone / Fax | 61 8 6382 0137 / |
Dividends
More: Invex Therapeutics Dividend history, yield and payout ratio
Dividend yield
-
Dividend amount
$-
Payout ratio
0.00%
5Y Avg. yield
-%
Invex Therapeutics paid $- dividend and the ex-dividend date was 08 Dec 2023.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.IXC dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Feb 2026, following are the company executives and directors listed on Invex Therapeutics.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Ms. Carla Healy | Joint Company Secretary | ||
| Mr. Timothy Ryan Slate | Joint Company Secretary |
Profitability and management effectiveness
Profit margin
-208.16%
Operating margin
-103.51%
Return on assets
-7.65%
Return on equity
-8.72%
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Invex Therapeutics is 9.39M and its enterprise value is 4.02M. The enterprise value to revenue ratio of IXC is 17.55. The enterprise value to EBITDA ratio of IXC is -.
The IXC's stocks Beta value is 0.23 making it 77% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Invex Therapeutics (IXC)
Invex Therapeutics (ASX:IXC) Frequently Asked Questions
1. What is Invex Therapeutics's Stock Symbol?
Invex Therapeutics trades on ASX under the ticker symbol "IXC".
2. What is Invex Therapeutics's stock price today?
One share of IXC stock can currently be purchased for approximately $0.125.
3. How can I contact Invex Therapeutics?
Invex Therapeutics's mailing address is 38 Rowland Street Level 2 Subiaco WA 6008 Australia. The company can be reached via phone at 61 8 6382 0137.
4. What is Invex Therapeutics's official website?
The official website of Invex Therapeutics is https://www.invextherapeutics.com.